INBS
Intelligent Bio Solutions Inc.5.50
+0.00+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
5.28MP/E (TTM)
-Basic EPS (TTM)
-16.50Dividend Yield
0%Recent Filings
8-K
First reader shipment deployed
Intelligent Bio Solutions received and deployed the first shipment of drug screening readers from its new manufacturing partner Syrma Johari on February 25, 2026, validating scale-up and quality compliance. The partnership promises over 40% production cost savings, lifting gross margins by ~20 points annually, while doubled in-house test strip capacity boosts vertical integration. Deployments expand the U.K./Europe base. Production ramps throughout 2026.
8-K
Record 48% Q2 revenue growth
Intelligent Bio Solutions posted Q2 fiscal 2026 revenue of $897K, up 48% year-over-year, powered by reader sales doubling 104% to $247K while cartridges rose 33% to $517K. First-half revenue hit $2.01M, up 36%, with gross margins climbing 10 points to 49%. Reader surge builds recurring revenue base. $10M private placement closed January 2 bolsters cash to $12.2M current assets.
10-Q
Q2 FY2026 results
Intelligent Bio Solutions posted Q2 revenue of $897K, up 48% y/y and 48% q/q (derived), with gross profit jumping to $460K from $223K y/y as UK sales hit $847K. Operating loss widened to $2.6M from $2.3M y/y, driven by SG&A up 29% on marketing and wages, yet gross margins expanded sharply. Cash burned $4.4M on operations with no capex disclosed; quarter-end cash sat at $740K, bolstered by $9.4M subscription receivable (collected Jan 2026). Equity swelled to $10.9M via ATM and warrant raises. Diluted EPS of -$2.82 reconciles to 951K shares. Non-GAAP metrics not disclosed in the 10-Q. Nasdaq bid price compliance restored post reverse split. Going concern doubts linger over funding needs.
8-K
Q2 revenue up 48% YoY
Intelligent Bio Solutions announced preliminary unaudited results showing fiscal Q2 2026 revenue up 48% year-over-year, with H1 total hitting $2.01 million, a 36% rise. Reader sales more than doubled, fueling the razor-razorblade model via expanded installed base. Cartridge sales climbed 33%. Reader growth powers recurring revenue.
8-K
INBS starts codeine FDA trials
Intelligent Bio Solutions kicked off clinical studies on January 28, 2026, with Cliantha Research to validate codeine detection cut-offs for its fingerprint-based drug screening system, targeting FDA 510(k) clearance. The trial on 40 adults compares against an FDA-cleared device, with data due by March end. U.S. entry unlocks the world's largest drug screening market. Success hinges on trial results.
BGMS
Bio Green Med Solution, Inc.
1.34-0.01
BMRA
Biomerica, Inc.
2.37-0.08
HSCS
HeartSciences Inc.
2.31-0.16
IBO
Impact BioMedical, Inc.
0.44-0.02
IINN
Inspira Technologies Oxy B.H.N.
1.02-0.03
INMD
InMode Ltd.
14.48+0.15
INSP
Inspire Medical Systems, Inc.
115.51-3.75
IRME
IR-Med Inc.
0.02-0.01
NRXS
Neuraxis, Inc.
2.70+0.05
PMEDF
PREDICTMEDIX AI INC.
0.05-0.00